Vomiting, hallucinations, difficulty standing, and loss of consciousness are some of the side effects associated with consuming hemp-derived products containing delta-8-tetrahydrocannabinol (THC), the US Food and Drug Administration (FDA) issued a warning known from September 14th.

Deep sedation, slow breathing, irregular heart rate, and low blood pressure were some of the symptoms experienced in children who ingested a parent’s Delta-8-infused gummy candy purchased from a vape shop, the Centers for Disease Control and Others said Prevention (CDC) in a. with separate health notice 14 Sept.

The admonitions come after months of increasing consumer demand and poison control reports related to the cannabinoid naturally found in the cannabis sativa plant. Concentrated amounts of Delta-8 can be made from hemp-derived cannabidiol (CBD) and then incorporated into products sometimes marketed as “light weed” or “diet weed” according to the CDC.

Many states have already taken steps to ban or regulate Delta-8 products. 8 concentrations.

However, enforcement of these bans can face obstacles with online marketing and mislabeled Delta-8 products, which the CDC says can be confused with non-intoxicating hemp or CBD products.

“The health effects of Delta-8-THC have not been fully researched and understood,” the CDC stated. “However, Delta-8-THC is psychoactive and can have similar risks of impairment as Delta-9-THC. Therefore, products that contain delta-8-THC but are labeled with only delta-9-THC content rather than total-THC content are likely to underestimate the psychoactive potential of these products for consumers.

The CDC referred to a 1973 article that estimated Delta-8 to be about 50% -75% as psychoactive as Delta-9.

In its alert, “5 Things You Should Know About Delta-8 Tetrahydrocannabinol,” the FDA said Delta-8 poses “serious health risks,” and has not evaluated or evaluated Delta-8 products in any context for safe use approved, especially not to keep the cannabinoid out of the reach of children and pets.

“Some of these products can simply be referred to as ‘hemp products,’ which can mislead consumers who associate ‘hemp’ with ‘non-psychoactive’,” the FDA stated. “In addition, the FDA is concerned about the proliferation of products containing Delta-8-THC that are marketed for therapeutic or medical purposes, even though they have not been approved by the FDA. The sale of unauthorized products with unsubstantiated therapeutic claims not only violates federal laws, but can also endanger consumers because these products are not proven to be safe or effective. “

National Poison Control Centers received 661 cases of exposure to Delta-8 THC products between January 2018 and July 31, 2021, of which 660 occurred between January 1, 2021 and July 31, 2021, according to the FDA.

Of the 661 exposure cases:

  • 41% were unintended exposure to delta-8 THC and 77% of these unintended exposures were in pediatric patients under the age of 18.
  • 39% (258 cases) involved pediatric patients under the age of 18.
  • 18% (119 cases) had to be hospitalized, including children who had to be admitted to the intensive care unit after exposure to these products.

The 660 Delta-8 exposures were recorded using a new Delta-8-specific product code that the American Association of Poison Control Centers introduced into their National Poison Data System earlier this year, according to the CDC.

Specifically, the Michigan Poison Control Center reported two cases of serious Delta-8 side effects in the two children who took Delta-8 gums from one of their parents.

“Both children experienced deep sedation and slowed breathing, with an initial high heart rate that went on to a slowed heart rate and lower blood pressure,” the CDC said. “The children were taken to the intensive care unit for further monitoring and oxygen supplementation.”

According to the CDC, several factors can influence the type and severity of cannabis-related side effects, such as the type of cannabinoid ingested, the concentration, route of exposure, and the individual characteristics of the person who consumed the cannabinoid, such as age, weight, and gender.

Some other side effects caused by Delta-8 may include lethargy, uncoordinated movements, decreased psychomotor activity, slurred speech, increased heart rate that progresses to a slow heart rate, low blood pressure, difficulty breathing, sedation, and coma, according to the CDC.

Because the natural amount of Delta-8 in hemp is very low, chemicals are needed to convert other cannabinoids in hemp, such as CBD, to Delta-8 (i.e. synthetic conversion), according to the FDA.

The federal agency has raised concerns about this process because some manufacturers use potentially unsafe household chemicals through a synthetic process and may do so in uncontrolled or unsanitary environments, making the end products harmful to consumers.

In conclusion, the CDC said the surge of Delta-8 products in the cannabis and hemp markets has increased the availability of psychoactive products, even in states where adult cannabis use is not yet legal.

“Variations in product content, manufacturing practices, labeling, and potential misunderstandings of the psychoactive properties of Delta-8-THC can lead to unexpected effects for consumers,” said the CDC. “There have been reports of adverse events with products containing delta-8-THC that resulted in consumer treatment in the hospital or emergency room. Increasing reports of adverse events related to delta-8-THC, as well as preliminary reports of the emergence of other similarly manufactured products from cannabis, warrant continued monitoring and tracking of adverse events related to THC. “